Bristol Myers Squibb Director Michael McMullen Receives Routine Deferred Share Units

Transaction Summary

On September 30, 2026, Bristol Myers Squibb Co ($BMY) Director Michael R. McMullen acquired 560.897 Deferred Share Units at an implied price of $62.40 per unit, representing a total value of approximately $35,000.00.

Following this transaction, McMullen directly holds 17,050.601 Deferred Share Units, which include accrued deferred compensation and reinvested dividends under the company's 1987 Deferred Compensation Plan for Non-Employee Directors.

Filing Details & Mechanics

• Transaction Code: A (Grant, award, or other acquisition pursuant to Rule 16b-3).
• Settlement Terms: Each unit converts to one share of common stock upon settlement, which takes place when the reporting person ceases to serve on the board or at a pre-scheduled future date.
• Transaction Intent: This is standard, scheduled director compensation (likely quarterly board retainer fees paid in deferred equity equivalents) rather than an open-market discretionary purchase.

Market & Trading Significance

• Signal: Low / Neutral.
• Rationale: Routine equity awards and deferred compensation grants are customary for non-employee board members and do not indicate discretionary insider sentiment or immediate market impact.